NLRP3 and gout: Like Compound CY-09, Tranilast could be a potential pharmacological approach for the prevention/treatment of NLRP3-driven diseases such as type 2 diabetes, gouty arthritis, and cryopyrin-associated auto-inflammatory syndrome [318].